Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

-   Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 6 3% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating plan, existing cash, cash equivalents, including